On April 2, 2012, DePuy Orthopaedics, Inc. received a binding offer from Biomet for purchase of the DePuy Orthopaedics worldwide trauma business. The offer included the purchase of DePuy’s internal and external fixation products used in the treatment of bone fractures as well as the organization supporting this business. On May 24, 2012, DePuy Orthopaedics (DePuy) accepted the offer. The transaction with respect to the U.S., UK, Australia, New Zealand, Japan and the Le Locle (Swiss) facility is scheduled to close on June 15, 2012. The transaction will close later in other markets on a country-by-country basis.
We are in the process of transferring the DePuy Trauma business while working to ensure a smooth transition for all of our customers. In countries where the sale is scheduled to close on June 15, 2012, customers should contact their Biomet sales representatives to order and request support of the former DePuy Trauma products. Please be assured that we are committed to maintaining continuity of our product supply, quality and service throughout this process.
During the coming months, in countries where the transaction has closed, DePuy and its affiliates may be required to provide certain transitional administrative services to Biomet, such as logistics, regulatory, information technology, finance and operations pursuant to the terms of a global Transition Services Agreement (TSA). In some countries where the transaction doesn’t close on the initial closing date, DePuy or its affiliates will act as Biomet’s distributor in that country.
The transaction does not impact any other DePuy products. DePuy will continue to sell products across our broad reconstructive device portfolio, which includes a full range of hip, knee and extremity products. We will continue to devote our resources to opportunities for growth in joint reconstruction.